NYSE - Nasdaq Real Time Price USD

Haemonetics Corporation (HAE)

Compare
70.82 -0.34 (-0.47%)
As of 1:35 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Christopher A. Simon CEO, President & Director 3.6M 11.06M 1964
Mr. James C. D'Arecca CPA CFO, Executive VP & Financial Officer 1.31M -- 1971
Ms. Anila Lingamneni Executive VP & CTO 1.08M -- 1967
Ms. Michelle L. Basil Executive VP, General Counsel & Secretary 1.24M -- 1972
Mr. Josep Lluis Llorens Executive Vice President of Global Manufacturing & Supply Chain 1.08M 162.13k 1962
Ms. Farris Maryanne Maunsell VP, Chief Accounting Officer & Principal Accounting Officer -- -- 1976
Ms. Olga Guyette Senior Director of Investor Relations -- -- --
Mr. Rajeev Varma Senior Vice President of Strategy & Corporate Development -- -- --
Ms. Laurie A. Miller Senior VP & Chief Human Resources Officer -- -- 1974
Dr. Jan Hartmann M.D. Senior VP & Chief Medical Officer -- -- --

Haemonetics Corporation

125 Summer Street
Boston, MA 02110
United States
781 848 7100 https://www.haemonetics.com
Sector:?
Healthcare
Full Time Employees:?
3,657

Description

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Corporate Governance

Haemonetics Corporation’s ISS Governance QualityScore as of November 1, 2024 is 2. The pillar scores are Audit: 4; Board: 2; Shareholder Rights: 4; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 11:00 AM UTC

Haemonetics Corporation Earnings Date

Recent Events

September 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 8, 2024 at 12:00 PM UTC

Q1 2025 Earnings Call

August 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 30, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

July 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 7, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

May 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 28, 2024 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers